Fielmann is evolving from a defensive German optical leader into a transatlantic vision-care platform—Europe already restored ~25% margins, while the investment debate hinges on whether the US can be “Fielmannized” to match them.
Overview
Fielmann Group AG is transitioning from a defensive, dividend-oriented Central European optical leader into a transatlantic vision-care and audiology platform, marking the most consequential strategic shift in its history. The investment case hinges on a “Twin-Engine” framework: (1) the European fortress, where vertical integration and scale-driven price leadership have restored profitability despite weak macro conditions—Europe reached 24.8% adjusted EBITDA margin in 9M 2025, effectively hitting the ~25% Vision 2025 target; and (2) the US growth frontier, established through the acquisitions of SVS Vision and Shopko Optical, which currently dilutes Group margins but is improving rapidly as Fielmann applies its private label supply chain, lab capabilities, and omnichannel tech (“Fielmannization”). Financially, the recovery is clear: FY2024 sales were €2.3bn (+15% YoY) and 9M 2025 sales €1.84bn (+9%) with adjusted EBITDA up 18% YoY. Management reaffirmed FY2025 guidance (€2.5bn revenue; ~24% Group EBITDA margin) and outlined Vision 2035 ambitions of ~€4bn revenue by 2030 with a sustained ~25% EBITDA margin, implying mid-to-high single-digit CAGR via share gains and continued M&A. The market remains skeptical—shares trade around ~16x 2026E earnings—reflecting concerns over German consumer weakness and US integration risk. The report’s recommendation is HOLD/ACCUMULATE, encouraging investors to build positions as US margin expansion is validated quarter by quarter.